UBS Group AG Grows Stock Position in Arcus Biosciences, Inc. $RCUS

UBS Group AG grew its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 145.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 411,259 shares of the company’s stock after purchasing an additional 243,855 shares during the quarter. UBS Group AG’s holdings in Arcus Biosciences were worth $9,800,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. SBI Securities Co. Ltd. increased its position in shares of Arcus Biosciences by 13,547.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after purchasing an additional 2,845 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Arcus Biosciences by 17.5% during the 4th quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock valued at $77,000 after purchasing an additional 482 shares during the last quarter. Abich Financial Wealth Management LLC purchased a new stake in shares of Arcus Biosciences during the 3rd quarter valued at about $69,000. Bayforest Capital Ltd purchased a new stake in shares of Arcus Biosciences during the 4th quarter valued at about $190,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Arcus Biosciences by 184.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock valued at $69,000 after purchasing an additional 5,476 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Stock Down 4.5%

NYSE RCUS opened at $23.82 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.04 and a current ratio of 4.04. The company has a market capitalization of $3.00 billion, a P/E ratio of -7.49 and a beta of 0.87. Arcus Biosciences, Inc. has a one year low of $7.91 and a one year high of $28.72. The stock has a 50 day moving average price of $23.33 and a 200-day moving average price of $22.38.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). The firm had revenue of $17.00 million for the quarter, compared to the consensus estimate of $29.49 million. Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The firm’s revenue was down 39.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.14) earnings per share. As a group, equities analysts predict that Arcus Biosciences, Inc. will post -3.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RCUS has been the subject of a number of recent research reports. Wells Fargo & Company set a $23.00 price objective on Arcus Biosciences and gave the company an “equal weight” rating in a research note on Thursday, February 12th. Truist Financial upgraded Arcus Biosciences to a “strong-buy” rating in a research note on Monday, May 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Monday, April 20th. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Arcus Biosciences in a research note on Monday, March 2nd. Finally, Citigroup boosted their price objective on Arcus Biosciences from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.33.

Insider Activity at Arcus Biosciences

In other news, CFO Robert C. Goeltz II sold 7,763 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $25.63, for a total transaction of $198,965.69. Following the completion of the transaction, the chief financial officer directly owned 84,161 shares in the company, valued at approximately $2,157,046.43. This represents a 8.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.60% of the company’s stock.

Arcus Biosciences Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.